C2i Genomics

What C2i Genomics does

C2i Genomics is an AI-driven genomics company founded in 2019 that developed whole-genome minimal residual disease (MRD) testing for cancer monitoring. Its core product, the TrueMRD Platform, uses whole-genome sequencing (WGS) of cell-free DNA (cfDNA) from blood samples combined with proprietary AI algorithms to construct personalized tumor fingerprints for each patient, enabling detection of cancer recurrence months earlier than traditional imaging. The platform analyzes the entire tumor genetic landscape and matched germline DNA rather than pre-selected mutation panels, and supports tracking of tumor evolution over time to guide therapy intensification or de-intensification decisions. Its first commercial test addresses muscle-invasive bladder cancer (MIBC), with the underlying technology being validated for expansion to non-small cell lung, colorectal, pancreatic, and soft tissue sarcoma cancers through clinical trials including the UMBRELLA study with Gustave Roussy and the TOMBOLA trial in Denmark.

C2i Genomics operated as a B2B diagnostic technology company, providing AI-driven MRD testing services to oncology healthcare providers, urologists, and cancer treatment centers. The company was funded through a $12 million Series A in June 2020 and a $100 million Series B in April 2021, with investors including Casdin Capital, Silver Lake, NFX, The Mark Foundation for Cancer Research, Alexandria Real Estate Equities, and others. In February 2024, C2i Genomics was acquired by Veracyte Inc. (NASDAQ: VCYT), a publicly traded molecular diagnostics company. Post-acquisition, the TrueMRD technology is distributed through Veracyte's clinical diagnostics platform — healthcare providers order tests through Veracyte's provider portal and submit blood and tissue samples to Veracyte's laboratories for whole-genome sequencing and AI-driven analysis. Veracyte's broader testing portfolio, into which C2i is now consolidated, reported $135.1 million in Q1 2026 testing revenue growing 26% year-over-year.

Name

C2i Genomics

Legal name

C2i Genomics, Inc.

Website

https://c2i-genomics.com

Company type

Private

Founded year

2019

Operating status

Acquired

Headcount range

51–100 employees

Short description

C2i Genomics, acquired by Veracyte in February 2024, developed AI-driven whole-genome minimal residual disease testing for cancer monitoring. Its TrueMRD platform created personalized tumor fingerprints from cfDNA to detect recurrence earlier than imaging, serving oncology providers across multiple cancer types.

Ownership category

akta.pro rank

Product category

Molecular Cancer Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Cancer diagnostics
• Minimal residual disease
• Whole-genome sequencing
• Molecular diagnostics
• Cell-free DNA testing

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Testing Services: C2i Genomics generated revenue through providing AI-driven whole-genome MRD testing services to healthcare providers. Following the February 2024 acquisition by Veracyte, these capabilities are integrated into Veracyte's diagnostic portfolio, which reported testing revenue of $135.1 million in Q1 2026, growing 26% year-over-year.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

C2i Genomics provides AI-driven whole-genome minimal residual disease (MRD) testing services through its TrueMRD Platform, which uses whole-genome sequencing of cell-free DNA from blood samples to create personalized tumor fingerprints and detect cancer recurrence months earlier than traditional imaging. The platform is offered to healthcare providers and clinical laboratories as a laboratory-developed test, with the first commercial indication in muscle-invasive bladder cancer and expansion to additional cancer types via clinical trials. Following its February 2024 acquisition by Veracyte, the technology is distributed through Veracyte's clinical diagnostics platform and provider network.

Product overview

The TrueMRD Platform is a unified AI-driven diagnostic platform that provides whole-genome minimal residual disease (MRD) testing for cancer monitoring. Originally developed by C2i Genomics, the technology was acquired by Veracyte in February 2024. The platform uses whole-genome sequencing combined with proprietary AI algorithms to create personalized tumor signatures for each patient, enabling clinicians to detect cancer recurrence earlier and monitor tumor evolution over time. The first commercial test available is for muscle-invasive bladder cancer (MIBC), with the platform being validated across multiple cancer types including lung, colorectal, pancreatic, and soft tissue sarcomas through clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• TrueMRD Platform AI-driven whole-genome minimal residual disease (MRD) testing platform that uses whole-genome sequencing and proprietary AI algorithms to create personalized tumor fingerprints from each patient's tumor and germline DNA, enabling detection of cancer recurrence months earlier than imaging and tracking of tumor evolution over time via blood samples. First commercial test is for muscle-invasive bladder cancer (MIBC), with expansion to lung, colorectal, pancreatic, and soft-tissue sarcoma in clinical development. Sold to oncology healthcare providers, urologists, and clinical laboratories through Veracyte's provider portal post-acquisition.

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• TOMBOLA Trial (Denmark)coreStrategic or Co-development Partner · 1 September 2024Phase 3 multicenter trial in Denmark evaluating MRD testing approach to guide immunotherapy use at initial signs of relapse in muscle-invasive bladder cancer patients. Results demonstrate the clinical utility of the whole-genome approach for improving patient outcomes.
• Gustave RoussycoreStrategic or Co-development Partner · 1 February 2024Gustave Roussy exclusively selected Veracyte's TrueMRD platform for the UMBRELLA landmark trial assessing post-treatment strategies for patients with non-small cell lung, colorectal, pancreatic, and soft tissue sarcomas. The Phase 3 study evaluates pre-emptive immunotherapy for MRD-positive patients.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Foundation Medicine: Roche-owned comprehensive genomic profiling leader with growing MRD/Liquid CDx offerings; broad incumbent competing in oncology diagnostics with deeper payer relationships.
• Exact Sciences: Diversified cancer diagnostics company (Cologuard, Oncotype) with MRD ambitions through acquisitions (e.g., Thrive); a broad incumbent with deep commercial reach into oncology practices.
• NeoGenomics: Clinical oncology lab services provider expanding into MRD and liquid biopsy; comparable in serving oncologists with specialized cancer testing.

Emerging players

• Personalis: Genomics company offering tumor-informed MRD testing (NeXT Personal); directly competitive WGS-adjacent MRD approach targeting similar oncology providers.
• Tempus: AI-driven precision medicine company with multi-omics oncology testing including MRD/ctDNA capabilities; comparable AI-first technology approach and provider customer base.
• Resolution Bioscience: cfDNA-based liquid biopsy developer (now part of Agilent) focused on targeted oncology panels; comparable cfDNA technology stack serving pharma and clinical oncology.
• Adaptive Biotechnologies: ImmunoSEQ and clonoSEQ MRD products focus on blood cancers but represent an adjacent MRD franchise; comparable diagnostic platform model serving oncologists.

Direct peers

• Guardant Health: Guardant Reveal is a blood-based MRD test using cfDNA; competes head-to-head with TrueMRD in solid tumor monitoring and shares the oncology provider customer segment.
• Natera: Natera's Signatera is a leading tumor-informed MRD test using a targeted panel approach; directly comparable to TrueMRD in clinical use case (recurrence monitoring) and customer base (oncologists, urologists).

Regional players

• Burning Rock Biotech: China-based cancer genomics company with MRD/liquid biopsy offerings; comparable technology platform but primarily serves the Chinese market rather than competing directly in the US.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/C2iGenomics
• LinkedInlinkedin.com/company/c2i-genomics

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about C2i Genomics